<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-2125</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina General Integral]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Med Gen Integr]]></abbrev-journal-title>
<issn>0864-2125</issn>
<publisher>
<publisher-name><![CDATA[ECIMED]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-21252002000200014</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Índice de materia]]></article-title>
</title-group>
<aff id="A">
<institution><![CDATA[,  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2002</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2002</year>
</pub-date>
<volume>18</volume>
<numero>2</numero>
<fpage>173</fpage>
<lpage>173</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-21252002000200014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-21252002000200014&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-21252002000200014&amp;lng=en&amp;nrm=iso"></self-uri></article-meta>
</front><body><![CDATA[  <h2>Resumed</h2> <h4>&Iacute;ndice de materia</h4> <table width="97%" border="0">   <tr>      <td>AGENTES ANTIF&Uacute;NGICOS </td>     <td>11,13</td>   </tr>   <tr>      <td>AGENTES ANTIINFECCIOSOS DE QUINOLONA/uso terap&eacute;utico</td>     <td>8</td>   </tr>   <tr>      <td>AGENTES ANTITUBERCULOSOS</td>     <td>9 </td>   </tr>   <tr>      <td>AGENTES ANTIVIRALES/uso terap&eacute;utico</td>     <td>17 </td>   </tr>   <tr>      <td>AMOXILINA/uso terap&eacute;utico</td>     <td>12,15</td>   </tr>   <tr>      <td>ATENCI&Oacute;N PRIMARIA DE SALUD&nbsp;</td>     <td>7</td>   </tr>   <tr>      <td>ANTIBI&Oacute;TICOS/uso terap&eacute;utico </td>     <td>1,16</td>   </tr>   <tr>      <td>CANDIDIASIS VULVOVAGINAL/quimioterapia </td>     <td>11</td>   </tr>   <tr>      <td>CIFROFLOXACINO/uso terap&eacute;utico</td>     <td>18</td>   </tr>   <tr>      <td>COMBINACI&Oacute;N TRIMETROPIM-SULFAMETOXAZOL </td>     <td>18</td>   </tr>   <tr>      <td>COMPLICACIONES INFECCIOSAS DEL EMBARAZO/quimioterapia</td>     <td>3 </td>   </tr>   <tr>      <td>CUIDADOS AMBULATORIOS &nbsp;&nbsp;</td>     <td>4, 10</td>   </tr>   <tr>      <td>DERMATOPAT&Iacute;AS/diagn&oacute;sticos </td>     <td>19</td>   </tr>   <tr>      <td>EMBARAZO</td>     <td>5 </td>   </tr>   <tr>      <td>ENFERMEDADES DE LA U&Ntilde;A/quimioterapia</td>     <td>13</td>   </tr>   <tr>      <td>ENFERMEDADES DEL RECI&Eacute;N NACIDO/prevenci&oacute;n y control </td>     <td>16</td>   </tr>   <tr>      <td>ENFERMEDADES UROL&Oacute;GICAS/complicaciones</td>     <td>5 </td>   </tr>   <tr>      <td>ENSAYOS CONTROLADOS ALEATORIOS</td>     <td>15, 18</td>   </tr>   <tr>      <td>ESTUDIOS DE COHORTES</td>     <td>6 </td>   </tr>   <tr>      <td>FACTORES DE RIESGO&nbsp;</td>     <td>9, 12</td>   </tr>   <tr>      <td>HERPES ZOSTER/quimioterapia</td>     <td>17</td>   </tr>   <tr>      <td>INFECCIONES NEUMOC&Oacute;CICAS/quimioterapia </td>     <td>15</td>   </tr>   <tr>      <td>INFECCIONES POR ESCHERICHIA COLI/quimioterapia </td>     <td>5 </td>   </tr>   <tr>      <td>INFECCIONES ESTREPTOC&Oacute;CICAS/quimioterapia </td>     <td>16</td>   </tr>   <tr>      <td>INFLUENZA/quimioterapia </td>     <td>10</td>   </tr>   <tr>      <td>INTERACCIONES DE DROGAS </td>     <td>1 </td>   </tr>   <tr>      <td>LAISHMANIA BRAZILIENSIS</td>     <td>19</td>   </tr>   <tr>      <td>M&Eacute;DICOS DE FAMILIA </td>     <td>8 </td>   </tr>   <tr>      <td>METRONIDAZOL/uso terap&eacute;utico</td>     <td>3 </td>   </tr>   <tr>      <td>MUJERES &nbsp;</td>     <td>18</td>   </tr>   <tr>      <td>MYCOBACTERIUM MARINUM</td>     <td>19</td>   </tr>   <tr>      <td>NI&Ntilde;O </td>     <td>&nbsp;</td>   </tr>   <tr>      <td>NI&Ntilde;OS HOSPITALIZADOS</td>     <td>12</td>   </tr>   <tr>      <td>NEURALGIA</td>     <td>17 </td>   </tr>   <tr>      <td>NOCARDIA</td>     <td>19</td>   </tr>   <tr>      <td>OSTEOMELITIS/diagn&oacute;stico</td>     <td>2 </td>   </tr>   <tr>      <td>OTITIS EXTERNA/prevenci&oacute;n y control &nbsp;</td>     <td>14</td>   </tr>   <tr>      <td>OTITIS EXTERNA/quimioterapia </td>     <td>14</td>   </tr>   <tr>      <td>OTITIS MEDIA/quimioterapia</td>     <td>&nbsp;12</td>   </tr>   <tr>      <td>PIELONEFRITIS/quimioterapia &nbsp;</td>     <td>18</td>   </tr>   <tr>      <td>RESISTENCIA MICROBIANA A LAS DROGAS&nbsp;</td>     <td>4, 7, 12</td>   </tr>   <tr>      <td>SPOROTHRIX</td>     <td>19</td>   </tr>   <tr>      <td>TRABAJO DE PARTO PREMATURO&nbsp;</td>     <td>3</td>   </tr>   <tr>      <td>TUBERCULOSIS/quimioterapia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</td>     <td>9</td>   </tr>   <tr>      <td>TUBERCULOSIS RESISTENTE A MULTIDROGAS/quimioterapia </td>     <td>6 </td>   </tr>   <tr>     <td>VAGINOSIS/BACTERIANA/complicaciones </td>     <td>3</td>   </tr> </table>     <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>      ]]></body>
</article>
